Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Dermavant Sciences.

    Client Virtual Booth

    DERMAVANT SCIENCES

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Dermavant Sciences
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3780 Kilroy Airport Way Suite 250 Long Beach, CA 90806
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.dermavant.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/dermavant-sciences/
    Twitter
    Twitter
    https://twitter.com/dermavant

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Dermavant Submits Supplemental New Drug Application (sNDA) to FDA for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and...

    Details:

    Vtama (tapinarof) cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant and steroid-free, topical cream, for the treatment of atopic dermatitis in adults and children 2 years of age and older.


    Lead Product(s): Tapinarof

    Therapeutic Area: Dermatology Product Name: Vtama

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 14, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Dermavant Announces Positive Data from the ADORING Phase 3 Development Program in Atopic Dermatitis with VTAMA® (tapinarof) Cream, 1% in Adults and Chi...

    Details:

    Vtama (tapinarof) cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant and steroid-free, topical cream. It is being evaluated in phase 3 clinical trials for Atopic Dermatitis.


    Lead Product(s): Tapinarof

    Therapeutic Area: Dermatology Product Name: Vtama

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 11, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Dermavant Announces Positive Results from Phase 4 Open-Label Trial of VTAMA® (tapinarof) Cream, 1% for the Treatment of Plaque Psoriasis in the Head an...

    Details:

    Vtama (tapinarof) is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant and steroid-free, topical cream, for the treatment of plaque psoriasis in the head and neck region.


    Lead Product(s): Tapinarof

    Therapeutic Area: Dermatology Product Name: Vtama

    Highest Development Status: Phase IVProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 06, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Dermavant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Chi...

    Details:

    Vtama (tapinarof Cream 1%) is the first-in-class, steroid-free, once-daily topical treatment for moderate to severe atopic dermatitis in adults and children as young as two years old.


    Lead Product(s): Tapinarof

    Therapeutic Area: Dermatology Product Name: Vtama

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 16, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Dermavant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Chil...

    Details:

    Vtama (tapinarof Cream 1%) is the first-in-class, steroid-free, once-daily topical treatment for extensive atopic dermatitis in adults and children as young as two years old.


    Lead Product(s): Tapinarof

    Therapeutic Area: Dermatology Product Name: Vtama

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 15, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Dermavant Completes Enrollment of Two Phase 3 Clinical Trials of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Chil...

    Details:

    Vtama (tapinarof) is an aryl hydrocarbon receptor (AhR) agonist. It is the first-in-class, steroid-free, once-daily topical treatment for extensive atopic dermatitis in adults and children as young as two years old.


    Lead Product(s): Tapinarof

    Therapeutic Area: Dermatology Product Name: Vtama

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 13, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Dermavant to Present Data from Multiple Studies of Vtama® (tapinarof) cream, 1% at the 2023 Winter Clinical Dermatology Conference

    Details:

    Vtama (tapinarof Cream 1%) is the first-in-class, steroid-free, once-daily topical treatment for extensive atopic dermatitis in adults and children as young as two years old.


    Lead Product(s): Tapinarof

    Therapeutic Area: Dermatology Product Name: Vtama

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 12, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Dermavant Launches First Commercial for VTAMA® (tapinarof) cream, 1% as Part of a National, Multimedia Campaign for Adults with Plaque Psoriasis

    Details:

    VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults. VTAMA cream is the first and only steroid-free topical medication in its class, and it can be used long-term anywhere on the affected skin.


    Lead Product(s): Tapinarof

    Therapeutic Area: Dermatology Product Name: Vtama

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 22, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Dermavant Announces Highly Favorable Results from Pediatric Maximal Usage Study of VTAMA® (tapinarof) cream, 1% in Atopic Dermatitis

    Details:

    The study’s objective was to characterize the pharmacokinetics (PK) and safety of VTAMA (tapinarof) cream under maximal usage conditions in pediatric subjects with atopic dermatitis.


    Lead Product(s): Tapinarof

    Therapeutic Area: Dermatology Product Name: Vtama

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 08, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Dermavant to Present Data from Multiple Clinical Trials of VTAMA® (tapinarof) Cream, 1% at the 2022 Fall Clinical Dermatology Conference

    Details:

    VTAMA (tapinarof) cream, 1% is a topical prescription treatment approved by the FDA for adults with plaque psoriasis and is safe for regular, long-term use on all affected external skin areas.


    Lead Product(s): Tapinarof

    Therapeutic Area: Dermatology Product Name: Vtama

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 13, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search